Acuitas Medical

Acuitas Medical is a developer of analysis software for magnetic resonance imaging (MRI). The company's flagship product, fineSA, is a software package that analyzes MRI data to determine the spacing of structural elements within a region of interest at a resolution higher than achievable with conventional MRI.

The company, which is no longer active, had raised a total of $1.07 million over two funding rounds from five investors.

It is important to distinguish Acuitas Medical from Acuitas Therapeutics, a separate and active Vancouver-based biotechnology company. Acuitas Therapeutics was founded in February 2009 by Dr. Thomas Madden, Dr. Pieter Cullis, and Dr. Michael Hope. This company specializes in developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics. Its technology is a key component in the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, and Alnylam Pharmaceuticals' ONPATTRO®, a treatment for a rare genetic disease. Acuitas Therapeutics operates on a partnership-based business model, licensing its LNP technology to pharmaceutical companies, biotechnology firms, and academic institutions to help them develop and commercialize new therapies. The company does not develop its own drugs but focuses on enabling its partners' drug candidates. Their work also extends to developing therapies for cancer and infectious diseases like malaria, HIV, and tuberculosis, as well as advancing gene-editing therapeutics.

Keywords: MRI analysis software, magnetic resonance imaging, fineSA software, high-resolution imaging, medical imaging analysis, structural element spacing, Acuitas Medical, inactive company, venture capital